Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 14/20 | 0.42 |
| ▸ | CDK9 | P50750 | 14/20 | 0.42 |
| ▸ | CDK7 | P50613 | 13/20 | 0.42 |
| ▸ | CCNH | P51946 | 13/20 | 0.42 |
| ▸ | CDK4 | P11802 | 11/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 11/20 | 0.42 |
| ▸ | CCND1 | P24385 | 10/20 | 0.42 |
| ▸ | CCND3 | P30281 | 10/20 | 0.42 |
| ▸ | CDK1 | P06493 | 11/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27026812 | 0.90 | CCND1 (0.51) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL25400973 | 0.88 | CDK2 (0.49) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL24676732 | 0.82 | CDK2 (0.42) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL26267667 | 0.80 | CCNE1 (0.39) | CDK2CCNT1CDK9CDK7CCNH | |
| SCHEMBL26267740 | 0.79 | CDK2 (0.46) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL30537297 | 0.75 | PDK1 (0.33) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL25403994 | 0.75 | PDK1 (0.33) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL24676946 | 0.75 | CDK2 (0.43) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL24676023 | 0.75 | CDK2 (0.40) | CDK2CCNA2CCNT1CDK9CDK7 | |
| SCHEMBL24676540 | 0.74 | CDK2 (0.43) | CDK2CCNA2CCNT1CDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| WO-2023172957-A1 | THAIZOLE-PYRIMDIINE CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018136-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CDK2 4/4885CCNA2 37/4885CCNT1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.